Search results for "Hexanols"

showing 10 items of 23 documents

Coupling transcriptomics and behaviour to unveil the olfactory system of Spodoptera exigua larvae

2020

AbstractChemoreception in insects is crucial for many aspects related to food seeking, enemy avoidance, and reproduction. Different families of receptors and binding proteins interact with chemical stimuli, including odorant receptors (ORs), ionotropic receptors (IRs), gustatory receptors (GRs), odorant binding proteins (OBPs) and chemosensory proteins (CSPs). In this work, we describe the chemosensory-related gene repertoire of the worldwide spread pest Spodoptera exigua (Lepidoptera: Noctuide) focusing on the transcripts expressed in larvae, which feed on many horticultural crops producing yield losses. A comprehensive de novo assembly that includes reads from chemosensory organs of larva…

0106 biological sciencesMaleOlfactory systemanimal structuresOdorant bindingmedia_common.quotation_subject[SDV]Life Sciences [q-bio]Gene ExpressionOlfactionInsectSpodopteraSpodopteraReceptors Odorant01 natural sciencesBiochemistryLepidoptera genitaliaTranscriptomeBeet armywormExiguaAnimalsRNA-SeqPheromone bindingAcroleinGeneEcology Evolution Behavior and SystematicsComputingMilieux_MISCELLANEOUSmedia_commonGeneticsGenomic LibraryPropiophenonesbiologyGene Expression ProfilingfungiGeneral Medicinebiology.organism_classification010602 entomologyOrgan SpecificityLarvaOdorantsNoctuidaeInsect ProteinsFemaleHexanolsTranscriptome010606 plant biology & botany
researchProduct

The role of (E)-6-chloro-3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-styrylquinazolin-4(3H)-one in the modulation of cannabinoidergic system. A pilot stu…

2018

Abstract Background Compounds acting on endocannabinoid system regulate different neuronal processes through the cannabinoid receptors activation. The main aim of this study was determining whether the 2-styrylquinazolin-4(3H)-one 5, a structural analogue of rimonabant, was able to counteract the behavioural signs of the activation of the endocannabinoidergic system induced by CP 55.940. Methods Behavioural assessment was carried out using the tetrad task and the novel object recognition test. The endocannabinoidergic system activation was possible by the administration of CP 55.940 and 30 min after rats were tested in the tetrad task for the evaluation of the antinociceptive-, cataleptic-,…

0301 basic medicineAgonistCannabinoid receptormedicine.drug_classmedicine.medical_treatmentPilot ProjectsPharmacologyCannabinoidergicStyrenes03 medical and health sciences0302 clinical medicineRimonabantmedicineAnimalsRats WistarLatency (engineering)PharmacologyDose-Response Relationship DrugCannabinoid CB1 receptor antagonist Quinazolinone derivate Tetrad task Declarative memoryCannabinoidsChemistryRecognition PsychologyGeneral MedicineCyclohexanolsEndocannabinoid systemSettore CHIM/08 - Chimica FarmaceuticaRats030104 developmental biologyNociceptionQuinazolinesSettore BIO/14 - FarmacologiaCannabinoidLocomotion030217 neurology & neurosurgerymedicine.drug
researchProduct

Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses

2015

Rhodamine 123 (R123) transport substrate sensitizes P-glycoprotein (P-gp) to inhibition by compound 2c (cis-cis) N,N-bis(cyclohexanolamine)aryl ester isomer in a concentration-dependent manner in human MDR1-gene transfected mouse T-lymphoma L5178 cells as shown previously. By contrast, epirubicin (EPI) concentration changes left unaltered 2c IC50 values of EPI efflux. To clarify this discrepancy, defined molecular docking (DMD) analyses of 12 N,N-bis(cyclohexanolamine)aryl esters, the highly flexible aryl ester analog 4, and several P-gp substrate/non-substrate inhibitors were performed on human P-gp drug- or nucleotide-binding domains (DBD or NBD). DMD measurements yielded lowest binding e…

0301 basic medicineStereochemistryCell Culture TechniquesCancer drug resistance; Molecular docking; NN-Bis(cyclohexanolamine)aryl ester; P-glycoproteinPlasma protein bindingP-glycoproteinTransfectionBiochemistryRhodamine 123Substrate Specificity03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineCell Line TumorAnimalsRhodamine 123ATP Binding Cassette Transporter Subfamily B Member 1Binding siteP-glycoproteinEpirubicinPharmacologyBinding SitesbiologyMolecular StructureArylEstersCancer drug resistanceNCyclohexanolsMolecular Docking SimulationProtein Transport030104 developmental biologychemistryDocking (molecular)030220 oncology & carcinogenesisMolecular dockingbiology.proteinN-Bis(cyclohexanolamine)aryl esterEffluxBinding domainProtein Binding
researchProduct

The individual contribution of starter and non-starter lactic acid bacteria to the volatile organic compound composition of Caciocavallo Palermitano …

2017

Abstract The contribution of two starter ( Lactobacillus delbrueckii and Streptococcus thermophilus ) and nine non-starter ( Enterococcus casselliflavus , Enterococcus faecalis , Enterococcus durans , Enterococcus gallinarum , Lactobacillus casei , Lactobacillus paracasei , Lactobacillus rhamnosus , Pediococcus acidilactici and Pediococcus pentosaceus ) species of lactic acid bacteria (LAB) to the volatile organic compounds (VOCs) of Caciocavallo Palermitano cheese was investigated. The strains used in this study were isolated during the production/ripening of the stretched cheese and tested in a cheese-based medium (CBM). The fermented substrates were analyzed for the growth of the single …

0301 basic medicineStreptococcus thermophilusLactobacillus caseiSettore AGR/19 - Zootecnica SpecialeCheese based mediumLactobacillus paracaseiButanols030106 microbiologyCaciocavallo PalermitanoCaciocavallo Palermitano; Cheese based medium; Lactic acid bacteria; Ripened cheese; Volatile organic compounds; Food Science; MicrobiologyDiacetylXylenesMicrobiology03 medical and health sciencesEnterococcus gallinarumLactobacillus rhamnosusCheeseLactobacillusLactic acid bacteriaAnimalsLactobacillus rhamnosusStreptococcus thermophilusFood scienceLactobacillus delbrueckiiVolatile Organic CompoundsbiologyChemistryLacticaseibacillus rhamnosusPediococcus acidilacticifood and beveragesGeneral MedicineVolatile organic compoundbiology.organism_classificationCaciocavallo Palermitano; Cheese based medium; Lactic acid bacteria; Ripened cheese; Volatile organic compounds; Animals; Butanols; Butanones; Cheese; Diacetyl; Enterococcus; Fermentation; Hexanols; Lactobacillus casei; Lactobacillus delbrueckii; Lactobacillus rhamnosus; Milk; Streptococcus thermophilus; Volatile Organic Compounds; Xylenes; Food Science; MicrobiologyEnterococcus duransRipened cheeseButanonesLactic acid bacteria Caciocavallo Palermitano Ripened cheese Volatile organic compounds Cheese based mediumLacticaseibacillus casei030104 developmental biologyMilkFermentationbacteriaHexanolsLactobacillus caseiEnterococcusSettore AGR/16 - Microbiologia AgrariaFood Science
researchProduct

Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene

2009

Abstract Background Polymorphisms of cytochrome P450 2D6 (CYP2D6) have a significant effect on the pharmacokinetics of most tricyclic antidepressants. More than 150 alleles lead to four distinct phenotypes of drug metabolism. The phenotypes are described as ultrarapid, extensive, intermediate, and poor metabolizers. Therapeutic plasma levels of CYP2D6 substrates may be difficult to achieve. Here we describe a rapid and reliable procedure for CYP2D6*4, *3, *6, and *9 genotyping. Design and methods Serum concentrations of venlafaxine and its pharmacologically active metabolite, O-desmethylvenlafaxine, were measured in patients treated with the antidepressant venlafaxine, a substrate of CYP2D6…

AdultMaleCYP2D6GenotypeDNA Mutational AnalysisMolecular Sequence DataClinical BiochemistrySingle-nucleotide polymorphismBiologyPolymerase Chain ReactionSensitivity and Specificitydigestive systemGene DuplicationGene duplicationGenotypeHumansAlleleskin and connective tissue diseasesGeneGenotypingAllelesSequence DeletionGeneticsPolymorphism GeneticBase SequenceDepressionVenlafaxine HydrochlorideReproducibility of ResultsSequence Analysis DNAGeneral MedicineMiddle AgedCyclohexanolsMolecular biologyReal-time polymerase chain reactionCytochrome P-450 CYP2D6MutationAntidepressive Agents Second-GenerationFemaleClinical Biochemistry
researchProduct

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.

1996

A double-blind, randomized, parallel study in 167 hospitalized patients with major depression and melancholia was conducted to determine if rapidly escalated doses of venlafaxine produced an earlier response, compared with rapidly escalated doses of imipramine. The daily dose of venlafaxine was rapidly increased to 375 mg/day over a five-day period, was maintained at this level for 10 days, and then was reduced to 150 mg/day for the remainder of the study. The imipramine dose was rapidly increased to 200 mg/day over five days and was maintained at this level to the end of the study. The primary efficacy variables were time to response and time to sustained response on the HAM-D and MADRS. N…

AdultMaleImipraminePersonality Inventorymedicine.medical_treatmentVenlafaxineAntidepressive Agents TricyclicImipramineDrug Administration ScheduleDouble blindDouble-Blind MethodMelancholiamedicineHumansBiological PsychiatryDepression (differential diagnoses)Rapid responseChemotherapyDepressive DisorderDose-Response Relationship DrugVenlafaxine HydrochlorideParallel studyMiddle AgedCyclohexanolsPsychiatry and Mental healthTreatment OutcomeAnesthesiaAntidepressive Agents Second-GenerationFemalemedicine.symptomPsychologymedicine.drugJournal of psychiatric research
researchProduct

Subchronic Antidepressant Treatment with Venlafaxine or Imipramine and Effects on Blood Pressure and Heart Rate: Assessment by Automatic 24-Hour Moni…

1996

Venlafaxine is a new nontricyclic antidepressant inhibiting the reuptake of serotonin, noradrenaline, and, to a lesser extent, dopamine without antagonizing cholinergic, histaminergic, or noradrenergic receptors. Significantly, in a first placebo-controlled safety and efficacy study, high doses of venlafaxine increased blood pressure in some study subjects. In order to investigate further the effect of subchronic antidepressant drug treatment on blood pressure and heart rate, the effects of a conventional tricyclic (imipramine) and a structurally different phenethylamine antidepressant (venlafaxine) were compared. Sixteen inpatients with major depression (melancholic type) were treated for …

AdultMaleImipramineVenlafaxine HydrochlorideHemodynamicsBlood PressureVenlafaxineAntidepressive Agents TricyclicImipramineDouble-Blind MethodHeart RateHeart ratemedicineHumansPharmacology (medical)Psychiatric Status Rating ScalesDepressive Disorderbusiness.industryVenlafaxine HydrochlorideGeneral MedicineBlood Pressure Monitoring AmbulatoryMiddle AgedCyclohexanolsPsychiatry and Mental healthBlood pressureAnesthesiaCirculatory systemAntidepressive Agents Second-GenerationAntidepressantFemalebusinessmedicine.drugPharmacopsychiatry
researchProduct

Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine

2003

INTRODUCTION Melperone, a butyrophenone neuroleptic, is frequently used for its sleep-inducing properties. Despite its common use for more than 30 years, it is not yet characterized regarding its effects on cytochrome P450 s (CYPs). In an open pilot study, effects of melperone on the steady-state blood levels of venlafaxine, a recently introduced serotonin- and noradrenaline reuptake inhibiting antidepressant, were assessed. METHODS The dose-corrected serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed retrospectively in a therapeutic drug-monitoring (TDM) database comprising 94 patients. In addition, three patients received venlafaxine and melperone concomitantly a…

AdultMaleSleep Wake Disordersmedicine.medical_specialtyMelperoneVenlafaxine HydrochlorideVenlafaxinePharmacologyMethylationPharmacokineticsOral administrationCytochrome P-450 CYP2D6 InhibitorsInternal medicineDextrorphanmedicineHumansDrug InteractionsPharmacology (medical)AgedRetrospective StudiesChemistryVenlafaxine HydrochlorideGeneral MedicineDextromethorphanMiddle AgedCyclohexanolsButyrophenonesPsychiatry and Mental healthEndocrinologyCytochrome P-450 CYP2D6Drug Therapy CombinationFemaleDrug MonitoringReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

The Effect of Age, Sex, Smoking and Co-Medication on Serum Levels of Venlafaxine and O-Desmethylvenlafaxine under Naturalistic Conditions

2012

Venlafaxine (VEN) is a modern antidepressant which exerts both serotonin and norepinephrine reuptake inhibition. In this study we examined the influence of age, sex, smoking, and co-medication on serum levels of VEN and its metabolite O-desmethylvenlafaxine (ODVEN) in patients treated with VEN under naturalistic conditions.We retrospectively evaluated 478 TDM analyses of VEN requested in the Pychiatric University Hospitals of Mainz, Regensburg, and Würzburg. The determination of serum levels was performed by virtually identical chromatographic methods in the TDM laboratories of the participating hospitals.Serum levels varied widely on each dose level. Women had about 30% higher dose-correct…

AdultMalemedicine.medical_specialtyAdolescentVenlafaxine HydrochlorideVenlafaxinePharmacokineticsDesvenlafaxine SuccinateInternal medicinemedicineHumansPharmacology (medical)DosingAgedRetrospective StudiesAged 80 and overSex Characteristicsbusiness.industrySmokingAge FactorsVenlafaxine HydrochlorideRetrospective cohort studyGeneral MedicineMiddle AgedCyclohexanolsPsychiatry and Mental healthAnesthesiaVenAntidepressive Agents Second-GenerationAntidepressantDrug Therapy CombinationFemaleDrug Monitoringbusinessmedicine.drugSex characteristicsPharmacopsychiatry
researchProduct

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.

2006

SUMMARY Background: Venlafaxine (V) is a mixed serotoninand noradrenaline reuptake inhibitor used as afirst-line treatment of depressive disorders. It ismetabolized primarily by the highly polymorphiccytochrome P450 (CYP) enzyme CYP2D6 to yielda pharmacologically active metabolite, O-des-methylvenlafaxine (ODV), and to a lesser extentby CYP3A4, to yield N-desmethylvenlafaxine(NDV).Objectives: The aim of this study was to assesswhether the O-demethylation phenotype of V hasan impact on the pharmacokinetics and clinicaloutcome.Method: In 100 patients treated with V, serumconcentrations of V, ODV and NDV and theratios of concentrations ODV/V as a measure ofO-demethylation were determined. Indiv…

AdultMalemedicine.medical_specialtyCYP2D6AdolescentGenotypeVenlafaxine HydrochlorideVenlafaxineBiology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineDesvenlafaxine SuccinateGenotypemedicineHumansPharmacology (medical)Active metaboliteAgedPharmacologyDepressive DisorderPolymorphism GeneticfungiVenlafaxine HydrochlorideMiddle AgedCyclohexanols3. Good healthEndocrinologyCytochrome P-450 CYP2D6PharmacogeneticsAntidepressive Agents Second-GenerationFemaleReuptake inhibitor030217 neurology & neurosurgeryPharmacogeneticsmedicine.drugJournal of clinical pharmacy and therapeutics
researchProduct